Investor Presentaiton

Continence Care grew 6% in Q2 with contribution from all segments and regions Continence Care performance 7 9 6 7 5 11 8 7 6 ७ ।। ம • • 2,030 1,987 1,877 1,892 1,964 Q2 21/22 Q3 21/22 Revenues (DKKm) Q4 21/22 Organic growth (%) Q1 22/23 Q2 22/23 Reported growth (%) • Q2 2022/23 highlights Solid contribution to growth from all regions Sales growth in Europe was driven by the UK and Germany Continued good sales momentum in the US Emerging markets also contributed to growth, driven by LATAM Continued double-digit growth in markets with recent reimbursement openings, such as Poland, Australia, Japan and South Korea From a product perspective, the SpeediCathⓇ intermittent catheters portfolio, in particular compact, standard, and flexible catheters, were the main contributors to growth Collecting Devices continued to be negatively impacted by backorders. The backorder situation is now resolved, and production will be back to full capacity in Q3 Bowel Management contributed to growth led by solid growth in the US. PeristeenⓇ Plus continues to perform well and has replaced Peristeen as the standard of care in markets where the product has been launched Coloplast is launching Luja™, the new CE-marked male intermittent catheter with a Micro-hole Zone Technology. Luja is currently launched in four markets, and expected to be available in key markets over the next 9 months Coloplast

View entire presentation